BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Angelini G, Mura G, Messina G. Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: The importance of the secondary therapies. Exp Cell Res 2022;410:112968. [PMID: 34883113 DOI: 10.1016/j.yexcr.2021.112968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Dubinin MV, Starinets VS, Belosludtseva NV, Mikheeva IB, Chelyadnikova YA, Penkina DK, Vedernikov AA, Belosludtsev KN. The Effect of Uridine on the State of Skeletal Muscles and the Functioning of Mitochondria in Duchenne Dystrophy. IJMS 2022;23:10660. [DOI: 10.3390/ijms231810660] [Reference Citation Analysis]
2 Howard ZM, Gomatam CK, Piepho AB, Rafael-fortney JA. Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury. Front Pharmacol 2022;13:942660. [DOI: 10.3389/fphar.2022.942660] [Reference Citation Analysis]
3 Holm A, Hansen SN, Klitgaard H, Kauppinen S. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases. RNA Biol 2022;19:594-608. [PMID: 35482908 DOI: 10.1080/15476286.2022.2066334] [Reference Citation Analysis]
4 Matsuzaka Y, Hirai Y, Hashido K, Okada T. Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via nSMase2/Smpd3, Satellite, and Immune Cells in Duchenne Muscular Dystrophy. Int J Mol Sci 2022;23:1551. [PMID: 35163475 DOI: 10.3390/ijms23031551] [Reference Citation Analysis]